Farmers & Merchants Investments Inc. holds a $13.19 million stake in Pfizer Inc. (NYSE: PFE)

0

Farmers & Merchants Investments Inc. reduced its position in Pfizer Inc. (NYSE: PFE – Get Rating) by 1.1% in the first quarter, according to its most recent Form 13F filed with the Securities and Exchange Commission. The institutional investor held 254,742 shares of the biopharmaceutical company after selling 2,729 shares during the quarter. Farmers & Merchants Investments Inc.’s holdings in Pfizer were worth $13,188,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently changed their holdings in the company. Ullmann Wealth Partners Group LLC increased its stake in Pfizer shares by 6.2% in the first quarter. Ullmann Wealth Partners Group LLC now owns 5,759 shares of the biopharmaceutical company valued at $298,000 after buying 335 additional shares last quarter. Colonial River Wealth Management LLC increased its stake in Pfizer shares by 52.3% in the first quarter. Colonial River Wealth Management LLC now owns 20,988 shares of the biopharmaceutical company valued at $1,087,000 after purchasing an additional 7,206 shares last quarter. Annex Advisory Services LLC increased its stake in Pfizer shares by 23.6% in the first quarter. Annex Advisory Services LLC now owns 10,279 shares of the biopharmaceutical company valued at $532,000 after purchasing an additional 1,966 shares in the last quarter. Northcape Wealth Management LLC increased its stake in Pfizer by 27.2% during the first quarter. Northcape Wealth Management LLC now owns 41,580 shares of the biopharmaceutical company worth $2,153,000 after acquiring 8,880 additional shares last quarter. Finally, Redpoint Investment Management Pty Ltd increased its stake in Pfizer by 9.4% during the first quarter. Redpoint Investment Management Pty Ltd now owns 141,914 shares of the biopharmaceutical company worth $7,347,000 after acquiring 12,238 additional shares last quarter. Institutional investors and hedge funds hold 66.50% of the company’s shares.

Separately, SVP Jennifer B. Damico sold 4,218 shares of the company in a transaction dated Tuesday, June 7. The stock was sold at an average price of $53.96, for a total transaction of $227,603.28. Following the sale, the senior vice president now owns 10,846 shares of the company, valued at $585,250.16. The transaction was disclosed in a legal filing with the SEC, which is available on the SEC’s website. Additionally, Executive Vice Chairman William R. Carapezzi, Jr. sold 32,908 shares of the company in a trade dated Thursday, May 12. The stock was sold at an average price of $50.00, for a total value of $1,645,400.00. Following the sale, the executive vice president now directly owns 38,146 shares of the company, valued at approximately $1,907,300. The disclosure of this sale can be found here. Insiders have sold 41,126 shares of the company worth $2,075,003 in the past three months. Insiders own 0.05% of the shares of the company.

Several research analysts have published reports on PFE shares. Citigroup raised its price target on Pfizer from $46.00 to $57.00 and gave the stock a “neutral” rating in a Tuesday, April 5 research note. StockNews.com upgraded Pfizer from a “buy” rating to a “strong buy” rating in a Tuesday, April 19 research note. Barclays set a price target of $52.00 on Pfizer in a Monday June 27 research note. SVB Leerink launched a blanket on Pfizer in a Monday, May 23 report. They set a “market performance” rating and a target price of $55.00 on the stock. Finally, the Goldman Sachs group set a target price of $51.00 on Pfizer in a report on Wednesday, May 25. Nine investment analysts gave the stock a hold rating, ten gave the stock a buy rating and one gave the stock a high buy rating. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $57.26.

Pfizer stock opened at $52.31 on Friday. The company’s 50-day simple moving average is $50.66 and its 200-day simple moving average is $52.15. The stock has a market capitalization of $293.51 billion, a price/earnings ratio of 12.00, a P/E/G ratio of 0.63 and a beta of 0.76. Pfizer Inc. has a 12-month low of $38.93 and a 12-month high of $61.71. The company has a quick ratio of 1.13, a current ratio of 1.39 and a leverage ratio of 0.43.

Pfizer (NYSE:PFE – Get Rating) last released its results on Tuesday, May 3. The biopharmaceutical company reported earnings per share of $1.62 for the quarter, missing the consensus estimate of $1.66 per ($0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The company posted revenue of $25.66 billion in the quarter, compared to analyst estimates of $24.73 billion. During the same period a year earlier, the company posted EPS of $0.93. The company’s quarterly revenue increased by 76.8% compared to the same quarter last year. As a group, sell-side analysts expect Pfizer Inc. to post EPS of 6.61 for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Wednesday, June 29 will receive a dividend of $0.40. This represents an annualized dividend of $1.60 and a yield of 3.06%. The ex-dividend date is Thursday July 28. Pfizer’s payout ratio is 36.70%.

Pfizer profile (Get an evaluation)

Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceuticals worldwide. It offers drugs and vaccines in various therapeutic areas, including cardiovascular, metabolic and women’s health under the Premarin Family and Eliquis brands; biologics, small molecules, immunotherapies and biosimilars under the brands Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena and Braftovi; and sterile injectable and anti-infective drugs, and oral COVID-19 treatment under the brands Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid.

Further reading

Want to see which other hedge funds hold PFEs? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Pfizer Inc. (NYSE:PFE – Get Rating).

Institutional ownership by quarter for Pfizer (NYSE:PFE)



Get news and reviews for Pfizer Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.

Share.

Comments are closed.